Melanoma is among the most aggressive forms of cancer. Our latest retrospective analysis showed that recombinant human interferon-alpha1b (IFN-a1b) led to significantly prolonged survival with mild toxicity in patients with stage IV melanoma. Based on this clinical finding, the current study sought to investigate the influence of IFN-a1b on the antitumor immunity of melanoma, with interferon-alpha2b (IFN-a2b) used as a control.
Background
Melanoma is one of the most aggressive skin cancers, with a high mortality rate. The emergence of immune checkpoint blockers (ICBs) like programmed death-1 (PD-1) neutralizing antibodies and gene-targeted therapy, especially BRAF inhibitors, has led to prolonged survival in patients with advanced melanoma [1] . However, the response rate of melanoma patients who accept ICBs therapy is relatively low [2] . Moreover, BRAF mutant is infrequently seen in Chinese melanoma patients, which hinders the application of gene-targeted therapy [3] . Hence, there is still an unmet need for the development of effective treatments specifically applicable to melanoma patients in China.
Interferon-alpha (IFN-a) proteins are a class of homologous cytokines that belong to the family of type I IFNs. IFN-a proteins can activate janus kinase-signal transducer and activator of transcription 1 (JAK-STAT1) pathways, which ultimately results in the activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, which are not only involved in antiviral response, but are also important to immune surveillance of tumors, including melanoma [4, 5] . In 1995, the FDA approved high-dose IFN-a2b (HDI) as adjuvant therapy for highrisk melanoma [6] . However, the clinical application of IFN-a2b has been hampered by its severe toxicity, which prompted exploration of the use of other IFN-a subtypes in the treatment of melanoma.
IFN-a1 is another major subtype of IFN-a, with 80% of its amino acid sequence homologous with IFN-a2 [7, 8] . A previous phase I clinical trial reported that, in 18 patients with metastatic malignancies who received recombinant IFN-a1b therapy for over 8 weeks, 6 patients (5 with renal cell carcinoma and 1 with malignant hemangioendothelioma) showed progression-free survival for over 1 year, indicating a potential antitumor effect of IFN-a1b [9] . Encouragingly, our latest retrospective analysis showed that a recombinant product of IFN-a1b, which was developed by a Chinese genetic engineering group and has been approved for treatment of melanoma by the Chinese FDA, led to a median survival of 14.1 months in patients with stage IV melanoma, and only 5.6% of the patients had severe adverse events (unpublished data). These data demonstrate that IFN-a1b is a promising drug for the treatment of Chinese melanoma patients.
Based on our clinical findings, we sought to investigate the effect of IFN-a1b on the amount and the function of antitumor immune cells from melanoma patients, with IFN-a2b used as a control. In addition, the influence of IFN-a1b and IFN-a2b on the immune checkpoint axis of PD-1 and programmed deathligand 1 (PD-L1) was also evaluated.
Material and Methods
Patients Peripheral blood samples were collected from 45 patients with histologically verified melanoma in the Department of Dermatology, Xijing Hospital. Blood was drawn at the time of diagnosis, prior to therapy. Patients with current or recent therapy and other ongoing acute medical conditions were excluded. Written informed consent was obtained from all patients in the study. The characteristics of the melanoma patients involved in this study are listed in Supplementary Table 1 .
The progression stages of all cases were classified according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (seventh edition) [10] . The research protocol was designed and performed according to the principles of the Helsinki Declaration and was approved by the Ethics Review Board of Xijing Hospital, Fourth Military Medical University.
Cell culture and reagents
The FLFMM-34 cell line, derived from a Chinese patient with metastatic melanoma, was established in our laboratory [11] . The A2058 cell line was purchased from the American Type Culture Collection (ATCC). Both cell lines were cultured in Dulbecco's MEMV F12 medium (Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Recombinant human IFN-a1b (Hapgen ® , 50 μg/ml, 5×10 6 U/ml, specific activity 1.41×10 8 IU/mg in Madin-Darby bovine kidney [MDBK] cells) was obtained from Beijing Tri-Prime Gene Pharmaceutical Co. (Beijing, China). Recombinant human IFN-a2b (INTRON A ® , 1.8×10 7 U/1.2 ml, specific activity of 2×10 8 IU/mg) was obtained from Merck Sharp & Dohme Limited (Kenilworth, NJ, USA). The following directly-labeled monoclonal antibodies (mAbs) were purchased from BioLegend (San Diego, CA, USA): CD3-FITC (clone HIT3a), CD8-Percp/cyanine5.5 (clone SK1), CD56-PerCP/Cyanine5.5 (clone 5.1H11), CD69-PE (clone FN50), perforin-PE (clone dG9), PD-L1/PE(clone MIH2), PD-1/PE (clone EH12.2H7), and human leukocyte antigen-ABC (HLA-ABC)/FITC (clone W6/32).
Isolation, culture, and stimulation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were separated from peripheral blood by Ficoll-Hypaque (Dakewei, Shenzhen, China). Fresh PBMCs were washed and incubated overnight in RPMI-1640 culture medium (Invitrogen, Carlsbad, CA, USA) at 37°C in 5% CO 2 . They were then washed twice, and 2×10 6 cells were stimulated in each well of 6-well plates for 18 h in medium alone (negative control, NC), or in medium supplemented with IFN-a1b (1000 U/ml) or IFN-a2b (1000 U/ml), at 37ºC in humid atmosphere with 5% CO 2 .
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Evaluation of cell apoptosis and death
It is reported that the concentration of 1000 U/ml for IFN-a2b for in vitro experiments is equivalent to the average serum concentration (20 MU/m 2 ) of IFN-a2b in melanoma patients who receive intravenous HDI infusion therapy [12] , and IFN-a2b at this concentration can induce maximal phosphorylation of STAT1-pY701 in PBMCs [13] . We therefore selected 1000 U/ml as the stimulating dosage for both IFN-a1b and IFN-a2b.
The apoptosis of PBMCs was evaluated by flow cytometry with Annexin-V-FITC and propidium iodide (PI) staining (7 Sea Biotech, Shanghai, China) according to the manufacturer's instructions. PBMCs (1×10 6 cells) were treated as indicated for 48 h. At least 10 000 events were collected using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
The toxicity of IFN-a was evaluated by measuring lactate dehydrogenase (LDH) release using a CytoTox96 nonradioactive assay (Promega, Madison, WI, USA) according to the manufacturer's instructions [14] . PBMCs (1×10 5 cells) were cultured in 96-well plates and treated with IFN-a1b or IFN-a2b for 48 h. Their absorbance levels at 490 nm were recorded. We used corrected values to calculate the percent cytotoxicity according to the following formula: percent cytotoxicity=100×experimental LDH release (OD490)/maximum LDH release (OD490).
Flow cytometric analysis of cell subsets
PBMCs were stained for different cell surface markers and then were sorted by flow cytometry (BD FACS Calibur) into a CD3-CD56 + NK cell subset, a CD3 + CD56 + NKT subset, and a CD3 + CD8 + T cells subset (Supplementary Figure 1A-1F ). The following combinations of directly-labeled mAbs were also identified: CD3/CD56/CD69, CD3/CD8/CD69, CD3/CD8/PD-L1, and CD3/CD8/PD-1. For perforin evaluation, PBMCs were treated with Brefeldin A (1: 1000, eBioscience, San Diego, CA, USA) for 6 h, followed by fixing and permeabilizing with Cytofix/Cytoperm solution (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. Cells were first stained for surface antigens with CD3/CD56 or CD3/CD8 antibodies, and subsequently stained with anti-perforin antibody. A total of 10 000-100 000 gated events verified as lymphocytes according to their physical characteristics (FSC and SSC) were collected per sample. Analyses were performed using FlowJo V10 software (TreeStar, Ashland, OR, USA).
IFN-g ELISPOT assay
The interferon-g (IFN-g) release enzyme-linked immune absorbent spot (ELISPOT) assay was performed using a commercial kit (Human IFN-g ELISPOT, Mabtech, Stockholm, Sweden) according to the manufacturer's instructions. Briefly, fresh PBMCs were washed and incubated overnight in DAYOU serum-free medium (Dakewe, Beijing, China) at 37°C in 5% CO 2 . Then, PBMCs (2×10 5 cells/well) were plated in the IFN-g ELISPOT plate at 37°C and 5% CO 2 . Medium was used as a negative control, and the anti-CD3 antibody (1: 1000) was used as a positive control. After 48-h stimulation, cells were removed and plates were washed 5 times with PBS. Biotinylated detection anti-IFN-g mAb (1 μg/ml) was added into the wells, followed by a 2-h incubation at room temperature, and the plates were then incubated for a further 1 h at room temperature with diluted streptavidin-ALP (1: 1000) in PBS-0.5% FCS at 100 μl per well. The plates were then washed 5 times with PBS, followed by addition of substrate solution BCIP/NBT-plus. Tap water was used to stop the reaction until distinct spots appeared. All plates were evaluated by a computer-assisted ELISPOT reader (Cell Technology Inc., Jessup, MD, USA).
Detection of HLA-ABC and PD-L1 in human melanoma cells
To ascertain the expressions of HLA-ABC and PD-L1 in melanoma cells by flow cytometry (BD FACS Calibur), FLFMM-34 and A2058 cells were seeded at a density of 2.5×10 5 cells/well in 6-well plates and cultured in Dulbecco's MEMV F12 medium with or without INF-a1b/INF-a2b (1000 U/ml) for 48 h. Afterwards, the cells were harvested and incubated with HLA-ABC/FITC or PD-L1/PE antibodies for approximately 30 min at 4°C and then washed twice with PBS. The mean fluorescence intensity (MFI) of HLA-ABC expression and the percentage of PD-L1-positive cells were analyzed by flow cytometry with gates set for viable cells. MFI represents the average fluorescence intensity of each event and refers to the expression quantity of the parameter on each event.
Cell viability assay
Cell viability was measured by Cell Counting Kit-8 (CCK8) assay according to the manufacturer's instructions (7 Sea biotech, Shanghai, China). Briefly, FLFMM-34 cells and A2058 cells were seeded into 96-well plates (5×10 3 cells/well), cultured for 20 h, and stimulated with either medium (negative control) or medium containing IFN-a1b/IFN-a2b with a concentration gradient (1×10 5 , 2.5×10 5 , 5×10 5 , 1×10 6 U/ml). After stimulation for 48 h, cells were incubated with CCK8 solution for half an hour, and absorbance (A) at 450 nm was then analyzed for each well using a microplate reader (Model 680, Bio-Rad, Hercules, CA, USA). The data on cell growth were expressed as percent inhibition of control. The experiments were repeated 3 times with 4 wells for each concentration.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 7.0. The nonparametric Wilcoxon matched-pairs signed e922790-3 rank test was used to detect the apoptosis of PBMCs, the cytotoxicity of IFN-a to PBMCs, the effects of IFN-a on NK cells, NKT cells, and CD3 + CD8 + T cells, and on the production of IFN-g in PBMCs. MFI of HLA-ABC and the expression of PD-L1 in melanoma cells were estimated using the Mann-Whitney test. For comparison of parameters with CCK8, an unpaired t test was applied. All experiments were repeated at least 3 times. Median and interquartile range were measured for the Wilcoxon matched-pairs signed rank test and the Mann-Whitney test. For unpaired t test, data were presented as mean±standard deviation (SD). All P-values were two-tailed, and values of P<0.05 were considered statistically significant.
Results
IFN-a1b or IFN-a2b at the concentration of 1000 U/ml has no toxic effect on PBMCs
Our initial flow cytometry assay showed that the percentage of apoptotic cells in PBMCs stimulated by IFN-a1b or IFN-a2b at 1000 U/ml was not increased compared with control ( Figure 1A) . Consistently, subsequent LDH assay demonstrated no change in the death of PBMCs after exposure to IFN-a1b or IFN-a2b at 1000 U/ml for 48 h compared with control ( Figure 1B) . Therefore, IFN-a1b or IFN-a2b at the concentration of 1000 U/ml has no toxic effect on PBMCs.
IFN-a1b and IFN-a2b promote the activation of NK and NKT cells from melanoma patients CD3 -CD56 + NK cells and CD3 + CD56 + NKT cells are critical innate immune cells for first-line host defense and play important roles in antitumor immune response. We thus analyzed the influence of IFN-a1b and IFN-a2b on the population and the activation of NK cells and NKT cells from melanoma patients. Our flow cytometry assay showed that the percentages of CD3 -CD56 + NK cells ( Supplementary Figure 2A ) and CD3 + CD56 + NKT (Supplementary Figure 2B ) cells were not significantly changed in PBMCs incubated with IFN-a1b or IFN-a2b. However, both IFN-a1b and IFN-a2b could increase the percentage of CD3 -CD56 bright+ NK cell subset with predominant immunoregulatory function (Supplementary Figure 2C) , although the percentage of CD3 -CD56 dim+ NK cell subset with mainly cytotoxic effect failed to respond (Supplementary Figure 2D) . Moreover, IFN-a1b and IFN-a2b enhanced the membranous expression of CD69, which is a classical marker for immune cell activation, and the cytoplasmic level of perforin, which is a vital cytotoxic mediator in NK cells (Figure 2A , 2B) and NKT cells ( Figure 2C, 2D ) from melanoma patients, whereas the effects of IFN-a1b and IFN-a2b showed no significant difference.
Our findings indicate that IFN-a1b and IFN-a2b promotes activation of NK cells and NKT cells to a similar extent.
IFN-a1b and IFN-a2b have different effects on CD8 + T cells from melanoma patients
Given that CD8 + T cells play a central role in T cells-mediated cytotoxicity against tumor cells, we went on to analyze the influence of IFN-a1b and IFN-a2b on the immune function of CD8 + T cells. We found that the levels of CD69 ( Figure 3A ) and perforin ( Figure 3B ) in CD3 + CD8 + T cells from melanoma 
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patients were both increased by treatment with IFN-a1b or IFN-a2b, with no significant difference between the effects of the 2 stimulations.
Then, we analyzed the influence of IFN-a1b and IFN-a2b on the expression of PD-1 and PD-L1, which are negative regulators of antitumor immune response, and subsequently found that neither IFN-a1b nor IFN-a2b influenced the expression of PD-1 in CD3 + CD8 + cells ( Figure 3C) . Notably, IFN-a2b significantly upregulated the expression of PD-L1 in CD3 + CD8 + T cells, whereas IFN-a1b did not show this adverse effect ( Figure 3D ). 
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IFN-a1b and IFN-a2b prompt the production of IFN-g in PBMCs from melanoma patients Next, we analyzed the influence of IFN-a1b and IFN-a2b on the production of IFN-g, an important antitumor cytokine that can be induced by type I IFN. As expected, our ELISPOT assay showed that the production of IFN-g was enhanced in PMBCs from melanoma patients after treatment with IFN-a1b or IFN-a2b, and IFN-a2b seemed to be a stronger inducer of IFN-g than was IFN-a1b ( Supplementary Figure 3) .
IFN-a1b and IFN-a2b have discrepant influences on the immunogenicity and the growth of melanoma cells
IFN-a can elevate the expression of HLA-ABC in tumor cells, which makes tumor cells more susceptible to immune recognition and destruction. Accordingly, we found that IFN-a1b and IFN-a2b enhanced the expression of HLA-ABC in FLFMM-34 cells ( Figure 4A ) and A2058 cells ( Figure 4B ), which are 2 similarly metastatic melanoma cell lines, indicating that both IFN-a1b and IFN-a2b can promote the immunogenicity of melanoma cells. Furthermore, treatment with IFN-a1b or IFN-a2b increased the expression of PD-L1 on the surface of FLFMM-34 cells ( Figure 4C ) and A2058 cells ( Figure 4D ), but this unfavorable effect was stronger in the cells treated with IFN-a2b than IFN-a1b.
We compared the influence of IFN-a1b and IFN-a2b on the growth of melanoma cells by using CCK8 assay. We found that IFN-a1b significantly repressed the growth of FLFMM-34 cells at concentrations over 2.5×10 5 U/ml, whereas IFN-a2b failed to show a parallel effect ( Figure 4E ). For A2058 cells, IFN-a1b and IFN-a2b showed similar suppression of the growth of A2058 cells at concentrations of 2.5×10 5 U/ml and 5×10 5 U/ml. However, IFN-a1b exhibited a superior inhibition of the growth of A2058 cells than did IFN-a2b when the stimulating concentration reached 1×10 6 U/ml ( Figure 4F ). Collectively, our results demonstrate that IFN-a1b and IFN-a2b have different influences on the immunogenicity and the growth of melanoma cells.
Discussion
We investigated the mechanism underlying the therapeutic effect of IFN-a1b against melanoma. IFN-a1b enhanced the activity of NK cells, NKT cells, and CD3 + CD8 + T cells. Compared with IFN-a2b, IFN-a1b induced a relatively lower level of PD-L1 expression in melanoma cells and did not affect the expression of PD-L1 in CD3 + CD8 + T cells, demonstrating that the adverse effect of IFN-a1b on the immune checkpoint axis is weaker than that of IFN-a2b. IFN-a1b showed a much stronger inhibition of the proliferation of melanoma cells than did IFN-a2b.
It is reported that IFN-a promotes the activity and cytotoxicity of NK cells and CTLs [15, 16] . In melanoma patients who received IFN-a2b treatment, higher proportions of CD8 + T cells and CD56 bright NK cells in circulating blood cells have been observed [17, 18] . In this study, we also demonstrated the stimulatory effect of IFN-a1b on immune cell activity, as evidenced by increased levels of CD69 and perforin expression in NK cells, NKT cells and CD3 + CD8 + T cells, as well as an elevated proportion of CD3 -CD56 bright+ NK cells, all of which were equal to the effect of IFN-a2b. In addition, IFN-a1b facilitated the expression of HLA-ABC in melanoma cells, indicating that IFN-a1b enhances the immunogenicity of melanoma cells and overcomes the immune evasion of melanoma caused by HLA-ABC loss.
It has become increasingly clear that IFN-a has an adverse effect of upregulating immunosuppressive molecules such as PD-L1 [19, 20] . PD-L1 is expressed on the membrane of immune cells and tumor cells and can inhibit T cell response by binding to PD-1 [21] . Therefore, the upregulation of PD-L1 contributes to tumor immune evasion and correlates with a poor prognosis for patients with cancer [22] . Our study showed that either IFN-a1b or IFN-a2b could induce PD-L1 expression. However, in contrast to IFN-a2b, which showed substantial increase of PD-L1 expression in both melanoma cells and CD3 + CD8 + T cells, IFN-a1b did not influence the expression of PD-L1 in CD3 + CD8 + T cells and moderately upregulated PD-L1 in melanoma cells. Thus, IFN-a1b appears to be a stronger immune enhancer for melanoma patients due to its weaker adverse effect on the axis of PD-1 and PD-L1 compared to that of IFN-a2b.
Type I IFNs have been observed to stimulate the production of IFN-g in NK cells and CTLs [15] . Consistently, our study showed an increase of IFN-g production in PBMCs after treatment with IFN-a1b or IFN-a2b. IFN-g promotes antitumor immunity via mechanisms similar to type I IFN, such as activating NK cells and CTLs, enhancing tumor immunogenicity, and directly inhibiting tumor cell proliferation [23] . However, a growing body of evidence also indicates an immunosuppressive effect of IFN-g, which can promote tumor growth. Specifically, IFN-g can promote the expression of PD-L1 and PD-L2 in tumor cells and even in stromal cells, including immune-infiltrating cells, thus suppressing the effector function of T cells or NK cells [24] . The crosstalk between type I IFN and IFN-g and the dual role of IFNs in tumor immunity need further study.
Although the mechanism underlying the inhibition of IFN-a in tumor cell growth has not been fully clarified, previous studies indicated that IFN-a can cause cell cycle arrest and cell death in tumor cells [25] [26] [27] . A study focusing on the direct antiproliferative effect of IFNs reported that melanoma cell lines differed markedly in their sensitivity to different types of IFNs and even different concentrations of a single subtype [25] . In line with previous work, we also identified different sensitivities of the 2 melanoma cell lines to IFN-a1b and IFN-a2b, and IFN-a1b showed greater inhibition of the growth of melanoma cells. Notably, we observed that the sensitivity of A2058 to IFN-a1b and IFN-a2b was identical at low concentrations, while higher sensitivity to IFN-a1b than IFN-a2b occurred at the highest concentration. These results suggest a better antiproliferative effect of IFN-a1b than IFN-a2b at high concentrations. Considering the mild toxicity of IFN-a1b in clinical application, it may be feasible to utilize high-concentration IFN-a1b in the treatment of melanoma, especially by intratumoral injection, thus bringing about better clinical benefits than achieved with IFN-a2b.
Taken together, our results demonstrate that IFN-a1b can promote antitumor immunity in melanoma via enhancing the activity of NK cells, NKT cells, and CD3 + CD8 + T cells. Moreover, IFN-a1b possesses unique characteristics in antitumor response, inducing lower expression of PD-L1 and stronger inhibition on the proliferation of melanoma cells than IFN-a2b. Nevertheless, this study has several limitations. The sample size was relatively small. In addition, the present study performed in vitro may not accurately reflect the conditions in vivo. Thus, our findings need to be verified by experiments in an animal model or in further clinical trials.
Conclusions
Our findings demonstrate that IFN-a1b has an immunostimulatory activity similar to that of IFN-a2b and has milder adverse effect on immune checkpoints and stronger inhibitory effect on melanoma cell growth than IFN-a2b. Our study provides an explanation for the tumor regression following use of IFN-a1b in Chinese melanoma patients, and supports IFN-a1b as a promising medicine for the treatment of melanoma. 
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